Priority Meds Review
Best for: pending product verification
Priority Meds LLC (prioritymeds.com), 13575 58th St N Ste 200, Clearwater, FL 33760, is a 100% online, flat-dose-pricing cash-pay telehealth provider offering compounded semaglutide ($98.99–$112.99/mo with B12) and compounded tirzepatide ($170.99/mo with B6). All dosages billed at the same price across the escalation schedule.
Medium confidence · Last verified 2026-04-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Priority Meds is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide (with B12) | compounded | $113 |
| Compounded tirzepatide (with B6) | compounded | $171 |
✓ Pros
- •Flat-dose pricing (no dose-escalation increases) per competitor sources
- •B-vitamin co-compounding (sema+B12, tirz+B6) is a differentiator in the segment
- •Clearwater FL based US operation
✗ Cons
- •Stub entry — exact drug formulary, pricing tiers, states served, and pharmacy partners need a YMYL verification pass
- •Confidence is LOW until that pass is done
Ready to start with Priority Meds?
Starting at $113/month. See current pricing and start your free consultation.
Sources & methodology
Our Priority Meds review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Priority Meds
Editorial score · methodology
Editorial score · methodology
Alloy
Best for: women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory
Editorial score · methodology
Frequently Asked Questions
Ready to start with Priority Meds?
Starting at $113/month. See current pricing and start your free consultation.